https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Trastuzumab Deruxtecan Yields Promising Intracranial Activity in Patients With HER2+/HER2-Low Breast Cancer and Brain Metastases

Trastuzumab Deruxtecan Yields Promising Intracranial Activity in Patients With HER2+/HER2-Low Breast Cancer and Brain Metastases

Trastuzumab deruxtecan shows promising efficacy in treating HER2-positive metastatic breast cancer with brain metastases, offering hope for challenging cases.

administrator

Related Articles